IX Biopharma Ltd.

Summary

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in China, Australia, and Singapore. The company operates through Specialty Pharmaceutical and Nutraceutical segments. Its lead product candidate is Wafermine, a sublingual ketamine oral wafer for the treatment of acute moderate to severe pain, as well as for major depressive disorder. The company also offers Xativa, a sublingual cannabidiol wafer for the treatment of anxiety, relieving pain, reducing inflammation, and improving sleep quality; BnoX, a sublingual buprenorphine wafer for the management of acute and chronic moderate to severe pain; and Wafesil and Silcap for the treatment of male erectile dysfunction. In addition, it offers LumeniX for skin lightening and immunity; WafeRest for the promotion of sleep; and SL-NAD+ product. Further, the company promotes and markets nutritional and supplements products through pharmacies and health food shops, as well as through online; develops and commercializes of nutraceutical products; provides laboratory services; JD and Tmall e-commerce platforms in China; and markets and distributes products in Europe. iX Biopharma Ltd. was founded in 2008 and is headquartered in Singapore.